BioVie Inc

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders and liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

Blinded Phase 3 data of NE3107 in Alzheimer's appear to indicate robust cognitive and biomarker efficacy. Market is significantly undervaluing the probability of a successful data unblinding expected shortly after Thanksgiving. Potential to be the first neurodegenerative biotech to show significant improvement in cognition Alzheimer's disease with suspected disease modification.

BioVie: Cautiously Optimistic Ahead Of Phase 3 Alzheimer's Data Unblinding

BioVie is set to report topline data from its Phase 3 trial in Alzheimer's disease, with a high likelihood of reaching statistical significance. Blinded data from the trial showed a reduction in amyloid burden and cognitive improvements in about 75% of patients. NE3107, BioVie's drug candidate, appears to show efficacy across all hallmarks of Alzheimer's disease, including aging.

BioVie: Upcoming Phase 3 Readout In Alzheimer's May Create Significant Value

BioVie Inc (NASDAQ:BIVI) has presented data from its Phase 2b trial evaluating the efficacy and safety of its drug candidate BIV201 for liver disease at The American Association for the Study of Liver Diseases – The Liver Meeting in Boston, Massachusetts. The company said the trial showed that BIV201 in combination with the standard of care in patients with refractory ascites due to cirrhosis was well tolerated with no major difference in treatment-emergent adverse events when compared to the standard of care alone.

BioVie presents positive safety data from Phase 2 liver disease trial

Data Show that BIV201 in Combination with Standard of Care (SOC) is Well Tolerated with No Major Difference in Treatment-Emergent Adverse Events (TEAEs) Compared to SOC Alone

BioVie Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2023

ORLANDO, FL / ACCESSWIRE / November 10, 2023 / RedChip Companies will air interviews with DevvStream Holdings Inc. (CBOE:DESG)(OTCQB:DSTRF)(FSE:CQ0) and BioVie Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, November 11, at 7 p.m. Eastern Time (ET).

DevvStream Holdings Inc. and BioVie Inc. Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

CARSON CITY, Nev., Nov. 02, 2023 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the participation of its management team in the Truist Securities BioPharma Symposium, to be held in New York, NY, November 8- 9, 2023.

BioVie to Participate in the Truist Securities BioPharma Symposium

Management and Key Opinion Leader to Highlight Recent Data on NE3017 Presented at CTAD Conference Management and Key Opinion Leader to Highlight Recent Data on NE3017 Presented at CTAD Conference

BioVie to Host Conference Call and Webcast Wednesday November 1, 2023 at 8:00 AM ET

BioVie Inc (NASDAQ:BIVI) has announced that clinical safety data from its Phase 2 open-label study evaluating the efficacy and safety of BIV201, terlipressin administered as a continuous infusion, in patients with refractory ascites due to cirrhosis, will be highlighted in a late-breaking poster presentation at The American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting 2023, taking place from November 10 to 14, 2023 in Boston.   The company said the abstract titled "Safety and Tolerability of Continuous Infusion Terlipressin (Biv201) In Patients with Decompensated Cirrhosis and Refractory Ascites: A Phase 2, Randomized, Controlled, Open-Label Study" will be presented by BioVie's senior vice president of ascites and strategic initiatives Penelope Markham on November 13 from 1PM to 2PM.

BioVie to present clinical safety data from ascites Phase 2 trial at AASLD in November

CARSON CITY, Nev., Oct. 26, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that clinical safety data from the Company's Phase 2 open-label study evaluating the efficacy and safety of BIV201, terlipressin administered as a continuous infusion, in patients with refractory ascites due to cirrhosis, will be highlighted in a late-breaking poster presentation at The American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting® 2023 , taking place from November 10-14, 2023 in Boston, MA.

BioVie Announces Late-Breaking Abstract Presenting Clinical Safety Data from the Company's Ascites Phase 2 Trial Accepted for Presentation at AASLD – The Liver Meeting® 2023

BIVI presented yesterday blinded clinical, imaging and biomarker outcome data of it phase 3 Alzheimer's Disease trial. Consistent improvements were seen in all above measures, which is suggestive of a treatment effect, as such improvements would be unexpected for untreated Alzheimer's Disease patients. Above findings reduce uncertainty and considering the asymetric risk/reward, I am updating my rating to a "Buy".

BioVie: Bullish Signals From Blinded Data Presentation (Rating Upgrade)

BioVie Inc (NASDAQ:BIVI) said that blinded data presented at the 16th Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston suggests its drug candidate, NE3107, may have a significant impact on cognitive, biomarker, and imaging endpoints in mild to moderate Alzheimer's Disease (AD) patients. The findings from the recently completed Phase 3 clinical trial indicate NE3107 as a potential multi-mechanistic treatment for Alzheimer's, offering hope for patients dealing with the debilitating condition.

BioVie says blinded data points to hopeful Alzheimer's treatment potential

CARSON CITY, Nev., Oct. 25, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, announced that blinded data on cognitive, biomarker and imaging findings from the recently completed Phase 3 clinical trial (NCT04669028) of NE3107 in the treatment of mild to moderate Alzheimer's Disease (AD) were presented today as an oral presentation at the 16th Clinical Trials on Alzheimer's Disease (CTAD) in Boston, MA,

Blinded Data Presented at CTAD Suggest that NE3107 is Biologically Active and May Have Impact on Cognitive, Biomarker, and Imaging Endpoints Among Mild to Moderate Alzheimer's Disease Patients

Matrix Service

Nu Holdings

NU, MTRX and BIVI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 19, 2023.

Best Momentum Stocks to Buy for October 19th

Enlivex Therapeutics Ltd

Intapp

Vericel

INTA, NU, ENLV, VCEL and BIVI have been added to the Zacks Rank #1 (Strong Buy) List on October 19, 2023.

New Strong Buy Stocks for October 19th

CARSON CITY, Nev., Oct. 19, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that blinded data on cognitive, biomarker, and imaging findings from the recently completed Phase 3 clinical trial (NCT04669028) of NE3107 in the treatment of mild to moderate Alzheimer's Disease will be presented during an oral presentation at the upcoming 16th Clinical Trials on Alzheimer's Disease (CTAD), to be held in Boston, MA from October 24-27, 2023.

BioVie to Present Blinded Data on NE3107 in the Treatment of Mild to Moderate Alzheimer's Disease at CTAD

What sets BioVie Inc (NASDAQ:BIVI) apart from many of its biotechnology peers is the fact it has appointed a Chief Social Impact Officer whose role is to drive the company's people-focused social impact initiatives.   Holding this position is Sarah Hoit, who has a personal connection to Alzheimer's, the neurodegenerative disease which is the focus of BioVie's clinical research efforts.

BioVie complements its Alzheimer's clinical research program with social impact initiatives

BioVie Inc (NASDAQ:BIVI) said the last patient has completed their final visit at week 30 in their Phase 3 study of investigational therapy NE3107 in patients with mild to moderate Alzheimer's Disease (AD), and it expects to announce topline data from the trial in November or December. BioVie's shares moved higher on the news, adding 4.6% to US$3.40 in pre-market trading.

BioVie to announce topline data from Phase 3 Alzheimer's Disease trial by year-end

CARSON CITY, Nev., Sept. 26, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that the last patient has completed the last visit at week 30 in its multicenter, randomized, placebo-controlled Phase 3 study (NCT04669028) of NE3107 in patients with mild to moderate Alzheimer's Disease (AD).

BioVie Announces Completion of Last Patient Treatment Visit in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer's Disease

CARSON CITY, NV / ACCESSWIRE / September 20, 2023 / As researchers continue to hunt for better treatments for neurodegenerative disease, one of the biggest breakthroughs in decades has been the realization that chronic inflammation may be playing a key role in the onset and progression of debilitating diseases like Alzheimer's and Parkinson's disease. That's led biotechs like BioVie (NASDAQ:BIVI) to turn the focus to treatments that block or alter inflammation as a way to also stop the neurodegeneration causing the progressively worsening symptoms.

BioVie's Lead Drug Candidate Aims To Treat Neurodegenerative Disease By Targeting Inflammation

CARSON CITY, Nev., Sept. 19, 2023 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the participation of its management team in the Cantor Fitzgerald Global Healthcare Conference, to be held in New York, NY, September 26-28, 2023.

BioVie to Participate in the Cantor Fitzgerald Global Healthcare Conference

BioVie Inc (NASDAQ:BIVI) has unveiled early data from its Phase 3 study of its investigational drug NE3107 in patients with mild to moderate Alzheimer's Disease, highlighting the preliminary baseline metabolic and inflammation characteristics of the study population. The data was presented as a poster titled “Metabolic Dysregulation in Probable Alzheimer's Disease” by BioVie's chief medical officer Dr.

BioVie presents Alzheimer's study data on patient's baseline characteristics

Data from Phase 3 Trial of NE3107 Presented as Poster at the 148 th American Neurological Association Annual Meeting

BioVie Presents Data Highlighting Baseline Characteristics of Study Population in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer's Disease

In 2022, BioVie had reported impressive data from a small Phase 2 trial in Alzheimer's. In October-November 2023, the company will report topline data from its ongoing Phase 3 trial in Alzheimer's. The reported baseline data of the patients in the Phase 3 trial appears to match the drug's mechanism of action.

BioVie: Well-Powered Phase 3 Trial In Alzheimer's Could Greatly Benefit Investors

CARSON CITY, Nev., Sept. 07, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, is hosting today a virtual KOL event titled NE3107―Putting Data in Context, ahead of the upcoming Phase 3 results in Alzheimer's Disease. The event will take place today at 2:30pm ET. To register, click here.

BioVie Hosting Virtual KOL Event on NE3107 in Alzheimer's Disease Today, September 7, 2023

Galera Therapeutics

iSpecimen

23andMe

Singular Genomics Systems

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

News for BioVie Inc Stock (BIVI)